Pilar Llamas Sillero-rekin lankidetzan egindako argitalpenak (13)

2024

  1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis

  3. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

2022

  1. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 2, pp. 295-299

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  2. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  3. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

2019

  1. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2017

  1. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

    Chest, Vol. 151, Núm. 3, pp. 564-571

  2. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

    American Journal of Medicine, Vol. 130, Núm. 4, pp. 482.e1-482.e9

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

2006

  1. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: The FLEBUS study [7]

    Journal of Thrombosis and Haemostasis